Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbavance PK in Healthy Adults
NCT02073812Phase 1Completed
- Sponsor
- Rempex Pharmaceuticals
- Start
- Feb 2014
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vaborbactam in gram-negative bacterial infections, sponsored by Rempex Pharmaceuticals. Primary endpoint: Pharmacokinetics from baseline through the end of the study at 2 days. Started Feb 2014; status: completed.
02
Drugs
vaborbactam
03
Conditions
gram-negative bacterial infections
Beyond the preview
Go deeper on NCT02073812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02073812.